Table 1.
Genotype | Case | Control | P a | Crude OR (95% CI) |
P | Adjusted OR (95% CI) b |
P b |
---|---|---|---|---|---|---|---|
Guangdong province (HWE = 0.279) | |||||||
CC | 88 (32.00) | 195 (36.79) | 1.00 | 1.00 | |||
CG | 130 (47.27) | 243 (45.85) | 1.19 (0.85–1.65) | 0.312 | 1.18 (0.85–1.64) | 0.332 | |
GG | 57 (20.73) | 92 (17.36) | 1.37 (0.91–2.08) | 0.135 | 1.38 (0.91–2.10) | 0.127 | |
Additive | 0.305 | 1.17 (0.96–1.44) | 0.124 | 1.18 (0.96–1.44) | 0.120 | ||
Dominant | 187 (68.00) | 335 (63.21) | 0.177 | 1.24 (0.91–1.68) | 0.177 | 1.23 (0.91–1.68) | 0.183 |
Recessive | 218 (79.27) | 438 (82.64) | 0.243 | 1.25 (0.86–1.80) | 0.244 | 1.26 (0.87–1.82) | 0.223 |
Henan province (HWE = 0.386) | |||||||
CC | 29 (24.58) | 99 (35.36) | 1.00 | 1.00 | |||
CG | 67 (56.78) | 129 (46.07) | 1.77 (1.07–2.95) | 0.027 | 1.73 (1.03–2.89) | 0.037 | |
GG | 22 (18.64) | 52 (18.57) | 1.44 (0.76–2.76) | 0.266 | 1.42 (0.74–2.74) | 0.291 | |
Additive | 0.085 | 1.25 (0.92–1.70) | 0.158 | 1.23 (0.90–1.69) | 0.186 | ||
Dominant | 89 (75.42) | 181 (64.64) | 0.036 | 1.68 (1.03–2.73) | 0.037 | 1.64 (1.004–2.68) | 0.048 |
Recessive | 96 (81.36) | 228 (81.43) | 0.986 | 1.01 (0.58–1.75) | 0.986 | 1.00 (0.57–1.74) | 1.000 |
Combined (HWE = 0.164) | |||||||
CC | 117 (29.77) | 294 (36.30) | 1.00 | 1.00 | |||
CG | 197 (50.13) | 372 (45.93) | 1.33 (1.01–1.75) | 0.042 | 1.33 (1.01–1.75) | 0.045 | |
GG | 79 (20.10) | 144 (17.78) | 1.38 (0.97–1.95) | 0.071 | 1.38 (0.97–1.95) | 0.074 | |
Additive | 0.080 | 1.19 (1.01–1.41) | 0.043 | 1.19 (1.004–1.41) | 0.045 | ||
Dominant | 276 (70.23) | 516 (63.70) | 0.025 | 1.34 (1.04–1.74) | 0.025 | 1.34 (1.03–1.74) | 0.028 |
Recessive | 314 (79.90) | 666 (82.22) | 0.331 | 1.16 (0.86–1.58) | 0.331 | 1.16 (0.86–1.58) | 0.333 |
a χ2 test for genotype distribution in neuroblastoma cases and cancer-free controls
b Adjusted for age and gender
OR odds ratio, CI confidence interval
The values were in bold if the 95% CI excluded 1, or P<0.05